 LA JOLLA, Calif., Feb. 09, 2021 GLOBE NEWSWIRE -- Equillium, Inc. Nasdaq: EQ a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Y. Katherine Xu, Ph.D., partner at Decheng Capital, has been appointed to Equilliums board of directors, effective Thursday, February 4, 2021. 